AU2006342119B8 - Soluble human M-CSF receptor and uses thereof - Google Patents

Soluble human M-CSF receptor and uses thereof Download PDF

Info

Publication number
AU2006342119B8
AU2006342119B8 AU2006342119A AU2006342119A AU2006342119B8 AU 2006342119 B8 AU2006342119 B8 AU 2006342119B8 AU 2006342119 A AU2006342119 A AU 2006342119A AU 2006342119 A AU2006342119 A AU 2006342119A AU 2006342119 B8 AU2006342119 B8 AU 2006342119B8
Authority
AU
Australia
Prior art keywords
cancer
csfr
soluble
csf
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006342119A
Other languages
English (en)
Other versions
AU2006342119A1 (en
AU2006342119A8 (en
AU2006342119B2 (en
Inventor
Maja Deuter-Reinhard
Michael Kavanaugh
John Kunich
Cheng Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Xoma Technology Ltd USA
Original Assignee
Novartis AG
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Xoma Technology Ltd USA filed Critical Novartis AG
Publication of AU2006342119A1 publication Critical patent/AU2006342119A1/en
Priority to AU2012261609A priority Critical patent/AU2012261609A1/en
Application granted granted Critical
Publication of AU2006342119B2 publication Critical patent/AU2006342119B2/en
Publication of AU2006342119B8 publication Critical patent/AU2006342119B8/en
Publication of AU2006342119A8 publication Critical patent/AU2006342119A8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/53—Colony-stimulating factor [CSF]
    • G01N2333/535—Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2006342119A 2005-12-22 2006-12-21 Soluble human M-CSF receptor and uses thereof Active AU2006342119B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012261609A AU2012261609A1 (en) 2005-12-22 2012-12-10 Soluble human M-CSF receptor and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75321805P 2005-12-22 2005-12-22
US60/753,218 2005-12-22
US78613106P 2006-03-27 2006-03-27
US60/786,131 2006-03-27
PCT/US2006/048879 WO2007120252A2 (en) 2005-12-22 2006-12-21 Soluble human m-csf receptor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012261609A Division AU2012261609A1 (en) 2005-12-22 2012-12-10 Soluble human M-CSF receptor and uses thereof

Publications (4)

Publication Number Publication Date
AU2006342119A1 AU2006342119A1 (en) 2007-10-25
AU2006342119B2 AU2006342119B2 (en) 2013-01-10
AU2006342119B8 true AU2006342119B8 (en) 2013-05-09
AU2006342119A8 AU2006342119A8 (en) 2013-05-09

Family

ID=38609972

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006342119A Active AU2006342119B8 (en) 2005-12-22 2006-12-21 Soluble human M-CSF receptor and uses thereof

Country Status (8)

Country Link
US (2) US20100099123A1 (https=)
EP (1) EP1977238B1 (https=)
JP (2) JP2009521685A (https=)
KR (1) KR101358600B1 (https=)
CN (1) CN101379400A (https=)
AU (1) AU2006342119B8 (https=)
CA (1) CA2634945A1 (https=)
WO (1) WO2007120252A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
WO2010062401A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules
EP2950098A1 (en) * 2009-07-14 2015-12-02 National Institute of Advanced Industrial Science and Technology Glycan markers as measure of disease state of hepatic diseases
RU2427323C1 (ru) * 2010-02-25 2011-08-27 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ прогнозирования генерализации процесса при злокачественных опухолях костей
MX378336B (es) 2010-05-04 2025-03-10 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
ES2442991B1 (es) * 2012-08-14 2014-11-25 Fundación Md Anderson International España Método para el diagnóstico y/o pronóstico de linfomas
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
AU2015280362B2 (en) 2014-06-23 2021-03-04 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
PT3212670T (pt) 2014-10-29 2021-02-15 Bristol Myers Squibb Co Terapêutica de combinação para cancro
EA201791421A1 (ru) 2014-12-22 2017-10-31 Файв Прайм Терапьютикс, Инк. Антитела против csf1r для лечения pvns
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
SG11202001606XA (en) 2017-09-13 2020-03-30 Five Prime Therapeutics Inc Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
AU2728588A (en) * 1987-10-23 1989-05-23 Genetics Institute Inc. Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene
JPH0967400A (ja) * 1995-08-31 1997-03-11 Toray Ind Inc モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
US6610484B1 (en) * 1999-01-26 2003-08-26 Cytyc Health Corporation Identifying material from a breast duct
WO2004045532A2 (en) * 2002-11-15 2004-06-03 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
US20040209937A1 (en) * 2003-02-24 2004-10-21 Sugen, Inc. Treatment of excessive osteolysis with indolinone compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Baiocchi G et al, Cancer, 1991, 67:990-996 *
Rao Q et al, Chinese Journal of Cancer Research. 2001, 13(3):185-189 *
Storga D et al, Int. J. Exp. Path. 1992, 73:527-533 *

Also Published As

Publication number Publication date
JP2009521685A (ja) 2009-06-04
AU2006342119A1 (en) 2007-10-25
JP2012108155A (ja) 2012-06-07
WO2007120252A3 (en) 2008-10-09
US20140030738A1 (en) 2014-01-30
EP1977238A2 (en) 2008-10-08
KR20080085054A (ko) 2008-09-22
AU2006342119A8 (en) 2013-05-09
AU2006342119B2 (en) 2013-01-10
CA2634945A1 (en) 2007-10-25
EP1977238B1 (en) 2016-09-28
CN101379400A (zh) 2009-03-04
KR101358600B1 (ko) 2014-02-06
WO2007120252A2 (en) 2007-10-25
US20100099123A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
US20140030738A1 (en) Soluble human m-csf receptor and uses thereof
AU2018201760B2 (en) Folate Receptor Alpha as a Diagnostic and Prognostic Marker for Folate Receptor Alpha-Expressing Cancers
EP2467724B1 (en) Survival prognostic assay
WO2011031517A1 (en) Method and assay for determining fas expression
WO2011133770A2 (en) Salivary protein markers for detection of breast cancer
US20250172572A1 (en) Noninvasive method to quantify kidney function and functional decline
RU2671578C2 (ru) Способ прогнозирования риска возникновения рака или диагностирования рака у женщины
CN108139404A (zh) 特异性地识别、结合活性结构的REIC/Dkk-3蛋白的抗体、以及使用该抗REIC/Dkk-3抗体的癌治疗的监测
EP2895863B1 (en) New biomarkers for the diagnosis and/or prognosis of clear cell renal cell carcinoma
AU2012261609A9 (en) Soluble human M-CSF receptor and uses thereof
MX2008007881A (es) Receptor m-csf humano soluble y usos del mismo
CN110687284B (zh) 检测血清中six2自身抗体的试剂的应用
CN103558391A (zh) 可溶性人m-csf受体及其应用
US20130217030A1 (en) Infection prognostic assay
WO2013017891A2 (en) Assay
CN102597772B (zh) 5.9kDa肽的免疫学测定方法
JP2008537101A (ja) 薬物応答を予測するための前立腺特異的抗原の使用
WO2020101039A1 (ja) 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果判定
US20120301879A1 (en) Novel use of ca-125
HK1212762B (zh) 预测女性对象患癌症风险或诊断其癌症的方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ 60/786,131 27 MAR 2006 US AND 60/753,218 22 DEC 2005 US

FGA Letters patent sealed or granted (standard patent)
TH Corrigenda

Free format text: IN VOL 22 , NO 27 , PAGE(S) 3241 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME NOVARTIS AG; XOMA TECHNOLOGY LTD, APPLICATION NO. 2006342119, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO XOMA TECHNOLOGY LTD.

Free format text: IN VOL 27 , NO 1 , PAGE(S) 234 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME NOVARTIS AG; XOMA TECHNOLOGY LTD, APPLICATION NO. 2006342119, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO XOMA TECHNOLOGY LTD.

Free format text: IN VOL 22 , NO 39 , PAGE(S) 4600 UNDER THE HEADING AMENDMENTS - AMENDMENTS MADE UNDER THE NAME NOVARTIS AG; XOMA TECHNOLOGY LTD, APPLICATION NO. 2006342119, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO XOMA TECHNOLOGY LTD.